Contents:

1 Executive Summary 2 Methodologies 3 Table of Contents 3.1 List of Figures 3.2 List of Tables 3.3 List of Boxes 4 Antibody Drug Target Analysis in Oncology: What and Where Are We Targeting? 4 Antibody Drug Target Analysis in Oncology: What and Where Are We Targeting? 5 Antibody Drug Targets by Molecular Function 5.1 Carboxypeptidase Activity Targets 5.2 Catalytic Activity Targets 5.3 Cell Adhesion Molecule Activity Targets 5.4 Chaperone Activity Targets 5.5 Chemokine Activity Targets 5.6 Cofactor Binding Targets 5.7 Complement Activity Targets 5.8 Cytokine Activity Targets 5.9 DNA Topoisomerase Activity Targets 5.10 Extracellular Matrix Structural Constituent Targets 5.11 G-protein Coupled Receptor Activity Targets 5.12 Growth Factor Activity Targets 5.13 Hormone Activity Targets 5.14 Hydrolase Activity Targets 5.15 Intracellular Ligand-gated Ion Channel Activity Targets 5.16 Metallopeptidase Activity Targets 5.17 MHC Class I Receptor Activity Targets 5.18 Molecular Function Unknown Targets 5.19 Oxidoreductase Activity Targets 5.20 Peptide Hormone Targets 5.21 Protease Inhibitor Activity Targets 5.22 Protein Binding Targets 5.23 Receptor Activity Targets 5.24 Receptor Binding Targets 5.25 Receptor Signaling Complex Scaffold Activity Targets 5.26 Receptor Signaling Protein Tyrosine Phosphatase Activity Targets 5.27 RNA-directed DNA polymerase Activity Targets 5.28 Serine-type Peptidase Activity Targets 5.29 T Cell Receptor Activity Targets 5.30 Translation Regulator Activity Targets 5.31 Transmembrane Receptor Activity Targets 5.32 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 5.33 Transporter Activity Targets 5.34 Unclassified Targets 6 Antibody Drugs Targeting Signaling Pathways 6.1 Alpha6 Beta4 Integrin Signaling Pathway 6.1.1 Description of Pathway 6.1.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type 6.2 Androgen Receptor Signaling Pathway 6.2.1 Description of Pathway 6.2.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type 6.3 B Cell Receptor Signaling Pathway 6.3.1 Description of Pathway 6.3.2 Antibody Drugs by Target, Developmental Stage and Cancer Type 6.4 EGFR1 Signaling Pathway 6.4.1 Description of Pathway 6.4.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type 6.5 IL-2 Signaling Pathway 6.5.1 Description of Pathway 6.5.2 Antibody Drugs by Target, Developmental Stage and Cancer Type 6.6 IL-4 Signaling Pathway 6.6.1 Description of Pathway 6.6.2 Antibody Drugs by Target, Developmental Stage and Cancer Type 6.7 IL-6 Signaling Pathway 6.7.1 Description of Pathway 6.7.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type 6.8 Kit Receptor Signaling Pathway 6.8.1 Description of Pathway 6.8.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type 6.9 Notch Signaling Pathway 6.9.1 Description of Pathway 6.9.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type 6.10 T Cell Receptor Signaling Pathway 6.10.1 Description of Pathway 6.10.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type 6.11 TGF-beta Receptor Signaling Pathway 6.11.1 Description of Pathway 6.11.2 Antibody Drugs byTarget, Developmental Stage, and Cancer Type 6.12 TNF-alpha Signaling Pathway 6.12.1 Description of Pathway 6.12.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type 6.13 Wnt Signaling Pathway 6.13.1 Description of Pathway 6.13.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type 7 Antibodies Targeting Cancer Stem Cells 8 Targets of Antibody Conjugates 9 Antibody Drug Targets by Three Major Non Immunological Therapeutic Effects 9.1 Anti-Angiogenesis 9.2 Apoptosis 9.3 Protein Kinase Inhibitors 10 Antibody Targets and Drugs by Cancer Indications 10.1 Basal Cell Cancer 10.2 Biliary Cancer 10.3 Bladder Cancer 10.4 Bone Cancer 10.5 Brain Cancer 10.6 Breast Cancer 10.7 Cervical Cancer 10.8 Cervical Dysplasia 10.9 Colorectal Cancer 10.10 Endometrial Cancer 10.11 Esophageal Cancer 10.12 Fallopian Tube Cancer 10.13 Gastrointestinal Cancers 10.14 Head and Neck Cancer 10.15 Leukemias 10.16 Liver Cancer 10.17 Lung Cancers 10.18 Lymphomas 10.19 Melanoma 10.20 Mesothelioma 10.21 Myelodysplastic syndrome 10.22 Myelomas 10.23 Nasopharyngeal Cancer 10.24 Oesophageal Cancer 10.25 Ovarian Cancer 10.26 Pancreatic Cancer 10.27 Peritoneal Cancer 10.28 Prostate Cancer 10.29 Renal Cancers 10.30 Sarcomas 10.31 Thyroid Cancer 11 Expression Profiles of Antibody Drug Targets 11.1 Human Tissues and Cancer Tissues 11.2 Cancer Lines and Cells 12 Leukemia: An Introduction 12.1 Leukemia Disease Definitions 12.1.1 The Lymphoid Malignancies 12.1.2 The Myeloid Malignancies 12.2 Etiology & Pathophysiology of Leukemia 12.2.1 The Lymphoid Malignancies 12.2.2 The Myeloid Malignancies 12.3 Epidemiology of Leukemia 12.4 Prognosis of Leukemia 12.4.1 The Lymphoid Malignancies 12.4.2 The Myeloid Malignancies 13 Current Treatment Strategies of Leukemia 13.1 The Lymphoid Malignancies 13.2 The Myeloid Malignancies 14 Progress in Current Leukemia Treatment Strategies 14.1 The Lymphoid Malignancies 14.2 The Myeloid Malignancies 15 Key Therapeutic Strategies for Future Leukemia Therapies 15.1 Therapeutic type, Targets & Mechanisms 16 Competitive Landscape in Leukemia Drug Development: The Late Stage Pipeline 16.1 The Lymphoid Malignancies 16.2 The Myeloid Malignancies 17 Current Leukemia Drug Development: The Early Stage Pipeline 18 The Myeloid Malignancies 18.1 The Lymphoid Malignancies 19 Lymphoma: An Introduction 19.1 Disease Definition 19.2 Etiology & Pathophysiology 19.3 Epidemiology 20 Current Lymphoma Treatment Strategies 20.1 Hodgkin's Disease 20.1.1 Radiation Therapy 20.1.2 Chemotherapy 20.1.3 Transplantation 20.1.4 Treatment Option Overview 20.2 Non-Hodgkin's Lymphoma 20.2.1 Radiation Therapy 20.2.2 Chemotherapy 20.2.3 Immunotherapy 20.2.4 Bone Marrow and Peripheral Blood Transplants Watch and Wait 20.2.5 Treatment Option Overview 20.3 Prognosis 20.3.1 Hodgkin's Disease 20.3.2 Non-Hodgkin 21 Progress in Current Lymphoma Treatment Strategies 21.1 HODGKIN 21.2 NON-HODGKIN 21.3 Rituxan 21.4 Bexxar 21.5 Zevalin 22 Key Therapeutic Lymphoma Strategies 22.1 Antibodies & Immunostimulation 22.2 Small molecules: Apoptosis inducers & Kinase inhibitors 23 Competitive Landscape in Lymphoma Drug Development: The Late Stage Pipeline 24 Current Lymphoma Drug Development: The Early Stage Pipeline 25 Disclaimer 26 Drug Index 27 Company Index 28 Appendix I: Antibody Targets by Companies 29 Appendix II: Drugs Approved for the Treatment of Leukemia: A Historical Perspective 30 Appendix III: Selected Companies – Anticancer Pipelines Accentia BioPharmaceuticals Biogen Idec Cell Therapeutics Cephalon Chiron Corporation (Now Novartis) Eli Lilly Favrille Genentech Genitope Corporation Genmab Genta GlaxoSmithKline Immunomedics Inex Pharmaceuticals Millennium Pharmaceuticals Protein Design Labs Roche Sanofi-Aventis Seattle Genetics Wyeth 3.1 List of Figures Figure 1: Antibody Pipeline Maturity by Molecular Function Classes of Targets 1(3) Figure 2: Antibody Pipeline Maturity by Molecular Function Classes of Targets 2(3) Figure 3: Antibdody Pipeline Maturity by Molecular Function Classes of Targets 3(3) Figure 4: Pipeline Maturation of Carboxypeptidase Activity Targets Figure 5: Number of Antibody Drugs per Cancer Indication and Carboxypeptidase Activity Target Figure 6: Pipeline Maturation of Catalytic Activity Targets Figure 7: Number of Antibody Drugs per Cancer Indication and Catalytic Activity Target Figure 8: Pipeline Maturation of Cell Adhesion Molecule Activity Targets Figure 9: Number of Antibody Drugs per Cancer Indication and Cell Adhesion Molecule Activity Target Figure 10: Pipeline Maturation of Chaperone Activity Targets Figure 11: Number of Antibody Drugs per Cancer Indication and Chaperone Activity Target Figure 12: Pipeline Maturation of Chemokine Activity Targets Figure 13: Number of Antibody Drugs per Cancer Indication and Chemokine Activity Target Figure 14: Pipeline Maturation of Cofactor Binding Targets Figure 15: Number of Antibody Drugs per Cancer Indication and Cofactor Binding Target Figure 16: Pipeline Maturation of Complement Activity Targets Figure 17: Number of Antibody Drugs per Cancer Indication and Complement Activity Target Figure 18: Pipeline Maturation of Cytokine Activity Targets Figure 19: Number of Antibody Drugs per Cancer Indication and Cytokine Activity Target Figure 20: Pipeline Maturation of DNA Topoisomerase Activity Targets Figure 21: Number of Antibody Drugs per Cancer Indication and DNA Topoisomerase Activity Target Figure 22: Pipeline Maturation of Extracellular Matrix Structural Constituent Targets Figure 23: Number of Antibody Drugs per Cancer Indication and Extracellular Matrix Structural Constituent Target Figure 24: Pipeline Maturation of G-protein Coupled Receptor Activity Targets Figure 25: Number of Antibody Drugs per Cancer Indication and Extracellular G-protein Coupled Receptor Activity Target Figure 26: Pipeline Maturation of Growth Factor Activity Targets Figure 27: Number of Antibody Drugs per Cancer Indication and Extracellular Growth Factor Activity Target Figure 28: Pipeline Maturation of Hormone Activity Targets Figure 29: Number of Antibody Drugs per Cancer Indication and Hormone Activity Target Figure 30: Pipeline Maturation of Hydrolase Activity Targets Figure 31: Number of Antibody Drugs per Cancer Indication and Hydrolase Activity Target Figure 32: Pipeline Maturation of Ligand-gated Ion Channel Activity Targets Figure 33: Number of Antibody Drugs per Cancer Indication and Intracellular Ligand-gated Ion Channel Activity Target Figure 34: Pipeline Maturation of Metallopeptidase Activity Targets Figure 35: Number of Antibody Drugs per Cancer Indication and Intracellular Metallopeptidase Activity Target Figure 36: Pipeline Maturation of MHC Class I Receptor Activity Targets Figure 37: Number of Antibody Drugs per Cancer Indication and MHC Class I Receptor Activity Target Figure 38: Pipeline Maturation of Molecular Function Unknown Targets Figure 39: Number of Antibody Drugs per Cancer Indication and Molecular Function Unknown Target Figure 40: Pipeline Maturation of Oxidoreductase Activity Targets Figure 41: Number of Antibody Drugs per Cancer Indication and Oxidoreductase Activity Target Figure 42: Pipeline Maturation of Peptide Hormone Targets Figure 43: Number of Antibody Drugs per Cancer Indication and Peptide Hormone Target Figure 44: Pipeline Maturation of Protease inhibitor Activity Targets Figure 45: Number of Antibody Drugs per Cancer Indication and Protease Inhibitor Activity Target Figure 46: Pipeline Maturationof Protein Binding Targets Figure 47: Number of Antibody Drugs per Cancer Indication and Protein Binding Target Figure 48: Pipeline Maturation of Receptor Activity Targets 1 (2) Figure 49: Number of Antibody Drugs per Cancer Indication and Receptor Activity Target 1(2) Figure 50: Pipeline Maturation of Receptor Activity Targets 2 (2) Figure 51: Number of Antibody Drugs per Cancer Indication and Receptor Activity Target 2(2) Figure 52: Pipeline Maturationof Receptor Binding Targets Figure 53: Number of Antibody Drugs per Cancer Indication and Receptor Binding Target Figure 54: Pipeline Maturation of Receptor Signaling Complex Scaffold Activity Targets Figure 55: Number of Antibody Drugs per Cancer Indication and Receptor Signaling Complex Scaffold Activity Target Figure 56: Pipeline Maturation of by Receptor Signaling Protein Tyrosine Phosphatase Activity Targets Figure 57: Number of Antibody Drugs per Cancer Indication and Receptor Signaling Protein Tyrosine Phosphatase Activity Target Figure 58: Pipeline Maturation of RNA-directed DNA polymerase Activity Targets Figure 59: Number of Antibody Drugs per Cancer Indication and RNA-directed DNA polymerase Activity Target Figure 60: Pipeline Maturation of Serine-type Peptidase Activity Targets Figure 61: Number of Antibody Drugs per Cancer Indication and RNA Serine-type Peptidase Activity Target Figure 62: Pipeline Maturation of T cell Receptor Activity Targets Figure 63: Number of Antibody Drugs per Cancer Indication and T cell Receptor Activity Target Figure 64: Pipeline Maturation of Translation Regulator Activity Targets Figure 65: Number of Antibody Drugs per Cancer Indication and Translation Regulator Activity Target Figure 66: Pipeline Maturation of Transmembrane Receptor Activity Targets Figure 67: Number of Antibody Drugs per Cancer Indication and Transmembrane Receptor Activity Target Figure 68: Pipeline Maturation of Transmembrane Receptor Protein Tyrosine Kinase Activity Targets Figure 69: Number of Antibody Drugs per Cancer Indication and Transmembrane Receptor Protein Tyrosine Kinase Activity Target Figure 70: Pipeline Maturation of Transporter Activity Targets Figure 71: Number of Antibody Drugs per Cancer Indication and Transporter Activity Target Figure 72: Pipeline Maturation of Unclassified Targets Figure 73: Number of Antibody Drugs per Cancer Indication and Unclassified Target Figure 74: Antibody Pipeline Comparison of Targeted Signaling Pathways in Oncology Figure 75: Pipeline Maturation of Immunoconjugated Antibody Targets Figure 76: Number of Immunoconjugated Antibody Drugs per Cancer Indication and Target Figure 77: Generalized Illustration, Depicting the Key Elements Involved in the Apoptotic Pathways. 3.2 List of Tables Table 1: Molecular Functions versus Oncology Antibody Drug Targets Table 2: Cancer Antibody Pipeline Listed by Carboxypeptidase Activity Targets Table 3: Cancer Antibody Pipeline Listed by Catalytic Activity Targets Table 4: Cancer Antibody Pipeline Listed by Cell Adhesion Molecule Activity Targets Table 5: Cancer Antibody Pipeline Listed by Chaperone Activity Targets Table 6: Cancer Antibody Pipeline Listed by Chemokine Activity Targets Table 7: Cancer Antibody Pipeline Listed by Cofactor Binding Targets Table 8: Cancer Antibody Pipeline Listed by Complement Activity Targets Table 9: Cancer Antibody Pipeline Listed by Cytokine Activity Targets Table 10: Cancer Antibody Pipeline Listed by DNA Topoisomerase Activity Targets Table 11: Cancer Antibody Pipeline Listed by Extracellular Matrix Structural Constituent Targets Table 12: Cancer Antibody Pipeline Listed by G-protein Coupled Receptor Activity Targets Table 13: Cancer Antibody Pipeline Listed by Growth Factor Activity Targets Table 14: Cancer Antibody Pipeline Listed by Hormone Activity Targets Table 15: Cancer Antibody Pipeline Listed by Hydrolase Activity Targets Table 16: Cancer Antibody Pipeline Listed by Intracellular Ligand-gated Ion Channel Activity Targets Table 17: Cancer Antibody Pipeline Listed by Metallopeptidase Activity Targets Table 18: Cancer Antibody Pipeline Listed by MHC Class I Receptor Activity Targets Table 19: Cancer Antibody Pipeline Listed by Molecular Function Unknown Targets Table 20: Cancer Antibody Pipeline Listed by Oxidoreductase Activity Targets Table 21: Cancer Antibody Pipeline Listed by Peptide Hormone Targets Table 22: Cancer Antibody Pipeline Listed by Protease inhibitor Activity Targets Table 23: Cancer Antibody Pipeline Listed by Protein Binding Targets Table 24: Cancer Antibody Pipeline Listed by Receptor Activity Targets Table 25: Cancer Antibody Pipeline Listed by Receptor Binding Targets Table 26: Cancer Antibody Pipeline Listed by Receptor Signaling Complex Scaffold Activity Targets Table 27: Cancer Antibody Pipeline Listed by Receptor Signaling Protein Tyrosine Phosphatase Activity Targets Table 28: Cancer Antibody Pipeline Listed by RNA-directed DNA polymerase Activity Targets Table 29: Cancer Antibody Pipeline Listed by Serine-type Peptidase Activity Targets Table 30: Cancer Antibody Pipeline Listed by T cell Receptor Activity Targets Table 31: Cancer Antibody Pipeline Listed by Translation Regulator Activity Targets Table 32: Cancer Antibody Pipeline Listed by Transmembrane Receptor Activity Targets Table 33: Cancer Antibody Pipeline Listed by Transmembrane Receptor Protein Tyrosine Kinase Activity Targets Table 34: Cancer Antibody Pipeline Listed by Transporter Activity Targets Table 35: Cancer Antibody Pipeline Listed by Unclassified Targets Table 36: Antibody Drugs Targeting Signaling Pathways Table 37: Signaling Pathway Analysis of Oncology Antibody Drug Targets Table 38: Targets Linking Antibody Drugs to the Alpha6 Beta4 Integrin Signaling Pathway Table 39: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the Alpha6 Beta4 Integrin Signaling Pathway Table 40: Targets Linking Antibody Drugs to the Androgen Receptor Signaling Pathway Table 41: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the Androgen Receptor Signaling Pathway Table 42: Targets Linking Antibody Drugs to the B Cell Receptor Signaling Pathway Table 43: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the B Cell Receptor Signaling Pathway Table 44: Targets Linking Antibody Drugs to the EGFR1 Signaling Pathway Table 45: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the EGFR1 Signaling Pathway Table 46: Targets Linking Antibody Drugs to the IL-2 Signaling Pathway Table 47: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the IL-2 Signaling Pathway Table 48: Targets Linking Antibody Drugs to the IL-4 Signaling Pathway Table 49: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the IL-4 Signaling Pathway Table 50: Targets Linking Antibody Drugs to the IL-6 Signaling Pathway Table 51: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the IL-6 Signaling Pathway Table 52: Targets Linking Antibody Drugs to the Kit Receptor Signaling Pathway Table 53: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the Kit Receptor Signaling Pathway Table 54: Targets Linking Antibody Drugs to the Notch Signaling Pathway Table 55: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the Notch Signaling Pathway Table 56: Targets Linking Antibody Drugs to the T Cell Receptor Signaling Pathway Table 57: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the T Cell Receptor Signaling Pathway Table 58: Targets Linking Antibody Drugs to the TGF-beta Receptor Signaling Pathway Table 59: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the TGF-beta Receptor Signaling Pathway Table 60: Targets Linking Antibody Drugs to the TNF-alpha Signaling Pathway Table 61: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the TNF-alpha Signaling Pathway Table 62: Targets Linking Antibody Drugs to the Wnt Signaling Pathway Table 63: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the Wnt Signaling Pathway Table 64: Cell Surface Markers of Identified Cancer Stem Cells in Human Tumors Table 65: Signaling Pathways Involved in Stem Cell Self-Renewal Table 66: Immunoconjugated Antibody Targets According to Molecular Function of Target Table 67: Immunoconjugated Antibody Pipeline According to Target Table 68: Antibodies in Oncology Reported to Affect Angiogenesis Table 69 Antibodies in Oncology Reported to Affect Apoptosis Table 70: Antibody Drug Protein Kinase Targets Ranked by Probability of Carrying at Least One Driver Mutation, Conditional on the Gene-Specific Selection Pressures Table 71: Antibodies in Oncology Reported to Act as Protein Kinase Inhibitors Table 72: Cancer Indicaions by Number of Known Antibody Targets, Number of Antibody Drugs, and Highest Developmental Stage Table 73: Antibody Pipeline by Targets in Basal Cell Cancer Table 74: Antibody Pipeline by Targets in Biliary Cancer Table 75: Antibody Pipeline by Targets in Bladder Cancer Table 76: Antibody Pipeline by Targets in Bone Cancer Table 77: Antibody Pipeline by Targets in Brain Cancer Table 78: Antibody Pipeline by Targets in Breast Cancer Table 79: Antibody Pipeline by Targets in Cervical Cancer Table 80: Antibody Pipeline by Targets in Cervical Dysplasia Table 81: Antibody Pipeline by Targets in Colorectal Cancer Table 82: Antibody Pipeline by Targets in Endometrial Cancer Table 83: Antibody Pipeline by Targets in Esophageal Cancer Table 84: Antibody Pipeline by Targets in Fallopian Tube Cancer Table 85: Antibody Pipeline by Targets in Gastrointestinal Cancers Table 86: Antibody Pipeline by Targets in Head and Neck Cancer Table 87: Antibody Pipeline by Targets in Leukemias Table 88: Antibody Pipeline by Targets in Liver Cancer Table 89: Antibody Pipeline by Targets in Lung Cancers Table 90: Antibody Pipeline by Targets in Lymphomas Table 91: Antibody Pipeline by Targets in Melanoma Table 92: Antibody Pipeline by Targets in Mesothelioma Table 93: Antibody Pipeline by Targets in Myelodysplastic syndrome Table 94: Antibody Pipeline by Targets in Myelomas Table 95: Antibody Pipeline by Targets in Nasopharyngeal Cancer Table 96: Antibody Pipeline by Targets in Oesophageal Cancer Table 97: Antibody Pipeline by Targets in Ovarian Cancer Table 98: Antibody Pipeline by Targets in Pancreatic Cancer Table 99: Antibody Pipeline by Targets in Peritoneal Cancer Table 100: Antibody Pipeline by Targets in Prostate Cancer Table 101: Antibody Pipeline by Targets in Renal Cancers Table 102: Antibody Pipeline by Targets in Sarcomas Table 103: Antibody Pipeline by Targets in Thyroid Cancer Table 104: Expression Profiles of Antibody Drug Targets in Oncology Table 105: ALL Classification Table 106: Latest Approved Drugs for the Treatment of Leukemia Table 107: Kinase Inhibitors in Development for the Treatment of Leukemia Table 108: Near Term Progress Rituximab Table 109: Near Term Progress Oblimersen Table 110: Near Term Progress Alvocidib Table 111: Near Term Progress ATRA Table 112: Near Term Progress GVAX Table 113: Near Tearm Progress HuM195 Table 114: Near Term Progress Zarnestra Table 115: Near Term Progress Sorafenib Table 116: Near Term Progress Valspodar Table 117: Summary of Current Late Stage Pipeline Table 118: Near Term Progress CEP-701 Table 119: Near Term Progress PKC412 Table 120: Near Term Progress SU5416 Table 121: Near Term Progress PTK787 Table 122: Near Term Progress VNP40101M Table 123: Near Term Progress Troxacitabine Table 124: Near Term Progress Decitabine Table 125 Near Term Progress Bortezomib Table 126 Near Term Progress AG-858 Table 127: Near Term Progress bevacizumab Table 128: Near Term Progress OSI-461 Table 129: Near Term Progress Xcytrin Table 130: Near Term Progress AP23573 Table 131: Summary of Current Early Stage Pipeline Table 132 Drugs used in the treatment of lymphoma. Table 133 Summary of Strategies Enhancing Antibody Function Table 134 Cancer immunotherapy strategies. Table 135 Protein Kinase Targets in Clinical Trials for Lymphoma Table 136 Recent published studies Aldesleukin Table 137 Recent published studies Arsenic trioxide Table 138 Recent published studies BiovaxID Table 139 Recent published studies Bortezomib Table 140 Recent published studies epratuzumab Table 141 Recent published studies FavId Table 142 Recent published studies MyVax Table 143 Recent published studies Nelarabine Table 144 Recent published studies Genasense Table 145 Recent published studies Pixantrone Table 146 Recent published studies temsirolimus Table 147 Recent published studies Zanolimumab Table 148 Recent published studies Flavopiridol Table 149 Recent published studies bevacizumab Table 150 Recent published studies CMC-544 Table 151 Recent published studies galiximab Table 152 Recent published studies LY317615 Table 153 Recent published studies SGN-40 Table 154 Recent published studies Apolizumab Table 155 Recent published studies SGN-30 Table 156 Accentia BioPharmaceuticals’ Anticancer Pipeline Table 157 Biogen-Idec’s Anticancer Pipeline Table 158 Cell Therapeutics’ Anticancer Pipeline Table 159 Cephalon’s Anticancer Pipeline Table 160 Chiron´s Anticancer Pipeline Table 161 Eli Lilly’s Anticancer Pipeline Table 162 Favrille anticancer pipeline Table 163 Genentech’s Anticancer Pipeline Table 164Genitope’s Anticancer Pipeline Table 165 Genmab’s Anticancer Pipeline Table 166 Genta’s Anticancer Pipeline Table 167 GlaxoSmithKline’s Anticancer Pipeline Table 168 Immunomedics’ Anticancer Pipeline Table 169 Inex Pharmaceuticals’ Anticancer Pipeline Table 170 Millennium Pharmaceuticals’ Anticancer Pipeline Table 171 Protein Design Labs’ Anticancer Pipeline Table 172 Roche’s Anticancer Pipeline Table 173 Sanofi-Aventis anticancer pipeline Table 174 Seattle Genetics’ Anticancer Pipeline Table 175 Wyeth’s Anticancer Pipeline 3.3 List of Boxes Box 1: Major treatment regimes Box 2: CLL staging system Box 3: Updated REAL/WHO Classification for B-Cell Neoplasms Box 4: Quick Facts - Clofarabine Box 5: Quick Facts – Alemtuzumab Box 6: Quick Facts - Gemtuzumab Box 7: Quick Facts - Imatinib Box 8: Quick Facts - Rituximab Box 9: Quick Facts - Genasense Box 10: Quick Facts - Flavopiridol Box 11: Quick Facts - Atra Box 12: Quick Facts - Gvax Box 13: Quick Facts - Zarnestra Box 14: Quick Facts – BAY 43-9006 . Box 15: Quick Facts - Ceplene Box 16: Quick Facts - Valspodar Box 17: Quick Facts - CEP-701 . Box 18: Quick Facts - PKC412 Box 19: Quick Facts - SU5416 Box 20: Quick Facts - PTK787 Box 21: Quick Facts - Cloretazine Box 22: Company statement on progress Box 23: Quick Facts - Troxacitabine Box 24: Quick Facts - FK228 Box 25: Quick Facts - Decitabine . Box 26: Quick Facts - VELCADE Box 27: Velcade sales 2005 . Box 28: Quick Facts - AG-858 Box 29: Quick Facts - Avastin Box 30: Quick Facts - OSI-461 Box 31: Quick Facts - Xcytrin Box 32: Quick Facts - AP23573 Box 33 Possible Complications of Treatment Box 34 Updated REAL/WHO Classification for B-Cell Neoplasms Box 35 Subclassification of Stage Box 36 Updated REAL/WHO Classification for B-Cell Neoplasms Box 37 Updated REAL/WHO Classification for T-Cell and Putative NK-Cell Neoplasms Box 38 Staging subclassification system Box 39 Study details

Companies Mentioned

- Accentia BioPharmaceuticals - Biogen Idec - Cell Therapeutics - Cephalon - Chiron Corporation (Now Novartis) - Eli Lilly - Favrille - Genentech - Genitope Corporation - Genmab - Genta - GlaxoSmithKline - Immunomedics - Inex Pharmaceuticals - Millennium Pharmaceuticals - Protein Design Labs - Roche - Sanofi-Aventis - Seattle Genetics - Wyeth